Home Cart Sign in  
Chemical Structure| 939981-39-2 Chemical Structure| 939981-39-2

Structure of RG7112
CAS No.: 939981-39-2

Chemical Structure| 939981-39-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RG7112 is a potent, selective, first clinical, orally active MDM2-p53 inhibitor that crosses the blood-brain barrier, with an IC50 of 18 nM and a KD of 11 nM for binding to MDM2.

Synonyms: RO5045337

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RG7112

CAS No. :939981-39-2
Formula : C38H48Cl2N4O4S
M.W : 727.78
SMILES Code : C[C@@]1([C@](C)(N(C(C2=CC=C(C=C2OCC)C(C)(C)C)=N1)C(N3CCN(CC3)CCCS(=O)(C)=O)=O)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl
Synonyms :
RO5045337
MDL No. :MFCD18206914
InChI Key :QBGKPEROWUKSBK-QPPIDDCLSA-N
Pubchem ID :57406853

Safety of RG7112

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CML CD34+ cells 50nM 24h Assess the effect of RG7112 on CML CD34+ cells, results showed that RG7112 significantly increased p53 expression. PMC4913876
K562 cells 50µM 72h Assess the effect of RG7112 on K562 cells, results showed that K562 cells were unresponsive to RG7112 due to lack of p53. PMC4913876
GBM cell lines 0.52 μM 72 hours To evaluate the effect of RG7112 on cell proliferation and viability, results showed that MDM2-amplified cell lines were highly sensitive to RG7112 with an IC50 of 0.52 μM. PMC4842012
MDM4-amplified GBM cell lines 1.2 μM 72 hours To evaluate the effect of RG7112 on MDM4-amplified GBM cell lines, results showed that these cell lines exhibited intermediate sensitivity to RG7112 with an IC50 of 1.2 μM. PMC4842012
H1299 cells 5 μM 2 hours RG7112 blocks TOP2 β degradation by interfering with the association of MDM2 with TOP2 β, extending its half-life. PMC10806188
A549 cells 5 μM 2 hours RG7112 blocks TOP2 β degradation by interfering with the association of MDM2 with TOP2 β, extending its half-life. PMC10806188
NALM6 3.2 μM 48 hours To evaluate the cytotoxicity of RG7112 on p53 wild-type leukemia cells, the IC50 for NALM6 cells was 3.2 μM PMC4359964
RS4;11 1.4 μM 48 hours To evaluate the cytotoxicity of RG7112 on p53 wild-type leukemia cells, the IC50 for RS4;11 cells was 1.4 μM PMC4359964
JURKAT >10 μM 48 hours To evaluate the cytotoxicity of RG7112 on p53 mutant leukemia cells, the IC50 for JURKAT cells was >10 μM PMC4359964
CEM >10 μM 48 hours To evaluate the cytotoxicity of RG7112 on p53 mutant leukemia cells, the IC50 for CEM cells was >10 μM PMC4359964
MLL-ALL xenograft cells 0.1-0.35 μM 48 hours To evaluate the cytotoxicity of RG7112 on MLL-ALL xenograft cells, the IC50 was 0.1-0.35 μM PMC4359964
MSTO-211H 0.15 µM 3 days RG7112 showed inhibitory effects on mesothelioma cells with wild-type p53, with an IC50 value of 2.55 ± 0.43 µM PMC8260618
NCI-H226 0.15 µM 3 days RG7112 showed inhibitory effects on mesothelioma cells with wild-type p53, with an IC50 value of 2.55 ± 0.43 µM PMC8260618
NCI-H28 0.15 µM 3 days RG7112 showed inhibitory effects on mesothelioma cells with wild-type p53, with an IC50 value of 2.55 ± 0.43 µM PMC8260618

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice SCL-tTA-BCR-ABL double transgenic leukaemia model oral 10 μM 5 days Assess the effect of RG7112 on leukaemic stem cells, results showed that RG7112 in combination with CPI-0610 significantly reduced the survival of leukaemic stem cells. PMC4913876
Nude mice xenograft GBM models oral 7 mg/kg Injected on days 1, 5, and 9, totaling 3 times To evaluate the efficacy of RG7112 in MDM2-amplified GBM models, results showed that RG7112 significantly inhibited tumor growth and prolonged survival in mice. PMC4842012
Mice Wild-type mice Oral gavage 30 mg/kg Once daily for 5 days Enhance p53 activity, protect mice from radiation-induced gastrointestinal toxicity PMC6717251
BALB/c nude mice H1299 tumor xenograft model intravenous injection 50 μmol/kg and 100 μmol/kg Once daily for 14 days The combination of RG7112 with VP-16 synergistically inhibited tumor growth, reduced tumor volume and weight, and induced tumor cell apoptosis. PMC10806188
NOD/SCID mice MLL-ALL xenograft model Oral 50 mg/kg Twice, 6 hours apart To evaluate the in vivo efficacy of RG7112 against MLL-ALL xenograft models, results showed that RG7112 significantly prolonged mouse event-free survival and induced p53 up-regulation, cell cycle arrest, and apoptosis PMC4359964
BALB/c nu/nu mice mesothelioma xenograft model intraperitoneal injection 25 mg/kg three times on days 0, 3 and 6 RG7112 alone inhibited tumor growth, and the combination with Ad-delE1B further reduced tumor weight PMC8260618

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00623870 Hematologic Neoplasms PHASE1 COMPLETED 2025-11-12 Duarte, California, 91010, Uni... More >>ted States|New Brunswick, New Jersey, 08901, United States|New York, New York, 10065, United States|Houston, Texas, 77030, United States|Toronto, Ontario, M5G 2M9, Canada|Montreal, Quebec, H3T 1E2, Canada|Bologna, Emilia-Romagna, 40138, Italy|Roma, Lazio, 00161, Italy|Glasgow, G12 0YN, United Kingdom|Leeds, LS9 7TF, United Kingdom|Oxford, OX3 7LJ, United Kingdom Less <<
NCT00559533 Neoplasms PHASE1 COMPLETED 2025-11-12 Aurora, Colorado, 80045, Unite... More >>d States|Boston, Massachusetts, 02115, United States|New York, New York, 10065, United States|Houston, Texas, 77030, United States|San Antonio, Texas, 98229, United States|Bordeaux, 33076, France|Lyon, 69373, France Less <<
NCT01143740 Sarcoma PHASE1 COMPLETED 2025-03-11 Bordeaux, 33076, France|Lille,... More >> 59020, France|Lyon, 69373, France|Villejuif, 94805, France Less <<
NCT01164033 Neoplasms PHASE1 COMPLETED 2025-05-13 Scottsdale, Arizona, 85258, Un... More >>ited States|Kansas City, Kansas, 66160-7330, United States|Kensignton, Maryland, 20895, United States|Dallas, Texas, 75230, United States|San Antonio, Texas, 98229, United States Less <<
NCT01677780 Myelogenous Leukemia, Chronic,... More >> Neoplasms, Myelogenous Leukemia, Acute Less << PHASE1 COMPLETED 2017-06-26 Sarcoma Oncology Center, Santa... More >> Monica, California, 90403, United States|M.D Anderson Cancer Center; Oncology, Houston, Texas, 77030, United States|Cancer Therapy & Research Ctr; Dept Institute for Drug Development, San Antonio, Texas, 78229, United States|Princess Margaret Hospital, Medical Oncology & Haematology, Toronto, Ontario, M5G 2M9, Canada|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, 31059, France Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.37mL

0.27mL

0.14mL

6.87mL

1.37mL

0.69mL

13.74mL

2.75mL

1.37mL

References

 

Historical Records

Categories